The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus

Abstract

Adult-onset type 1 diabetes mellitus differs from the early onset form in terms of residual endogenous insulin secretion, comorbidities and baseline cardiorenal risk. Adjunct therapy with glucagon-like peptide 1 receptor agonists could offer benefits in this population of patients by preserving β-cell mass and function while also contributing to cardiorenal risk mitigation.